Abstract
OBJECTIVE:This study aimed to assess miRNA-195 expression in the tumor tissues from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy (NAC) and evaluate its correlation with various clinicopathological markers.METHODS:Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to evaluate the miRNA-195 expression in tumor tissues from a cohort of female breast cancer patients undergoing NAC. This expression was then correlated with the occurrence of several distinct breast cancer molecular subtypes and other clinicopathological variables.RESULTS:A total of 55 patients were included in this study, 28 (50.9%) of whom were treated using NAC. Tumor miRNA-195 expression was suppressed in breast cancer patients, regardless of their exposure to systemic treatments, histological grade, size, nodal status, and tumor-node-metastasis (TNM) staging. This was more pronounced in luminal and triple-negative patients, and patient’s response to NAC was correlated with an increase in miRNA-195 expression.CONCLUSION:miRNA-195 is downregulated in the tumor tissues of Brazilian breast cancer patients regardless of NAC exposure; this reinforces its role as a tumor suppressor and a potential biomarker for chemotherapy response.
Highlights
Breast cancer is the most common cancer among women, and there are an estimated 2.1 million new cases of breast cancer annually
The average age of the control group was 37.8±2.4 years and when we evaluated the breast cancer molecular subtypes we noted that the HER-2 group included 10 patients with luminal hybrid tumors and two patients with HER-2 overexpression
The comparative analysis of miRNA-195 expression in breast cancer and healthy breast tissues demonstrated a marked reduction in miRNA-195 expression in all the breast cancer patients included in this study, regardless of previous chemotherapy treatment (Figure 1)
Summary
Breast cancer is the most common cancer among women, and there are an estimated 2.1 million new cases of breast cancer annually. Breast cancer is the leading cause of cancer-related deaths in over 100 countries [1], and despite significant evolution in our understanding of breast cancer carcinogenesis and its molecular pathways, the development of noninvasive diagnostic and prognostic biomarkers remains an unmet need. Mammography is still considered the gold standard for the screening and early diagnosis of breast cancer in asymptomatic patients [2].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
